The number of biopharma buyouts overall last year did not rise, though more deals were struck in the “sweet spot”, and premiums saw a healthy rise.
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Bristol-Myers Squibb’s $74bn bid for Celgene led to a huge quarter, but a drop in the deal count could give pause to those hoping for a bumper year.
A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets, while buyers remain most interested…